Background. Small bowel neuroendocrine tumors (SBNETs) present frequently with metastases, yet little is known about the molecular basis of this progression. This study sought to identify the serial differential expression of genes between normal small bowel, primary small bowel neuroendocrine tumors, and liver metastases. Methods. RNA isolated from matched normal small bowel tissue, primary small bowel neuroendocrine tumors, and liver metastases in 12 patients was analyzed with whole transcriptome expression microarrays and RNA-Seq. Changes in gene expression between primary small bowel neuroendocrine tumors and normal small bowels, and liver metastases versus primary small bowel neuroendocrine tumors were calculated. Common genes that were differentially expressed serially (increasing or decreasing from normal small bowel to primary small bowel neuroendocrine tumors to liver metastases) were identified, and 10 were validated using qPCR. Results. Use of 2 transcriptome platforms allowed for a robust discrimination of genes important in small bowel neuroendocrine tumors progression. Serial differential expression was validated in 7/10 genes, all of which had been described previously in abdominal cancers, and with several interacting with members of the AKT, MYC, or MAPK3 pathways. Liver metastases had consistent underexpression of PMP22, while high expression of SERPINA10 and SYT13 was characteristic of both pSBTs and liver metastases. Conclusion. Identification of the serial differential expression of genes from normal tissues to primary tumors to metastases lends insight into important pathways for SBNETs progression. Differential expression of various genes, including PMP22, SYT13 and SERPINA10, are associated with the progression of SBNETs and warrant further investigation.
progress to metastatic disease by the time of presentation. Despite the increased incidence of these neoplasms, little is known regarding the genetic steps accompanying the transformation of primary neoplasms and their progression to metastases. Improved understanding of these changes would aid in the identification of genes and pathways important to the evolution of SBNETs and assist potentially in the development of new diagnostic and therapeutic strategies.
Exome sequencing of SBNETs has revealed nonrecurring mutations in a variety of genes as well as frequent sites of deletion or amplification involving genes in the AKT and SMAD pathways.
identification of the sites of unknown primaries, 7 and discrimination of SBNETs from pancreatic NETs in primaries and metastases. 8, 9 Transcriptome analysis also has the potential to improve our understanding of the pathways central to progression of primary neoplasms to metastases. Recognition of genes serially over or underexpressed beginning with normal tissue and primary neoplasms, followed by even greater differential expression in metastases, could contribute to this understanding. In this study, we set out to compare changes in whole transcriptome expression between normal small bowel, primary SBNETs, and synchronous SBNET liver metastases using 2 different but complimentary platforms to identify genes associated with this progression.
Methods

RNA isolation
Patients presenting to the University of Iowa with SBNETs were consented for genetic studies and entered into a tumor registry approverd by the institutional review board. Tissues collected during operative procedures performed on patients with SBNETs were placed in RNAlater solution (Thermo Fisher Scientific, Waltham, MA). Twelve patients who had histologic confirmation of SBNETs and tissue samples from normal small bowel (Nl), a primary SBNET (pSBT) and a SBNET liver metastasis (lMet) were selected for transcriptome analyses. RNA was isolated from tissues using the RNeasy Plus Universal Mini Kit (Qiagen, Valencia, CA) with DNA digestion and resuspension in H2O per the protocol recommended by the manufacturer. RNA quality was then assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) with a requirement that samples have RNA integrity numbers (RIN) > 6.
RNA sequencing
RNA-Seq was performed at the University of Iowa Institute of Human Genetics (Iowa City, IA) using the Illumina TruSeq protocol (Illumina, Inc., San Diego, CA). Total RNA (500 ng) was fragmented, converted to cDNA, and ligated to sequencing adaptors. The molar concentrations of the indexed libraries were measured using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and combined equally into pools for sequencing. The concentration of each pool was determined using the Illumina Library Quantification Kit and sequenced on the Illumina HiSeq 4000 genome sequencer using a 75 bp paired-end sequencing-by-synthesis chemistry. The resulting FASTQ data were then aligned using the human hg19 genome assembly for mapping and annotation. TopHat (version 2.1.0, Center for Computational Biology at Johns Hopkins University, Baltimore, MD) was used to perform mapping, Cuffquant for quantitation, and Cuffnorm and Cuffdiff for normalization and differential expression analysis. 10 The 10th percentile of the level of expression was added to the kilobase of transcript per million mapped reads values reported by Cuffdiff to regularize the expression values in order to diminish artifacts of large-or small-fold change values as a result of a measured value for expression being close to zero. Statistically significant expression change was determined by the false discovery rate (FDR) adjusted P value (Q value).
Whole transcriptome microarrays
A total of 10 ng of total RNA was extracted and converted to cRNA utilizing the GeneChip WT Pico Reagent Kit (Affymetrix, Inc., Santa Clara, CA); then cRNA was hybridized to the GeneChip Human Transcriptome Array 2.0 (HTA; Affymetrix), and fluorescence was measured using the GeneChip Scanner 3000 (Affymetrix). Data were processed using the Affymetrix Expression and Transcriptome Analysis consoles, and comparisons were tested using analysis of variance (ANOVA) with significant differential expression defined as ANOVA P value and FDR P value < .05.
Expression data analysis
Genes with significant differential expression between pSBTs and Nls, lMets and Nls, and lMets and pSBTs by RNA-Seq were identified using a regularized, log-fold change >1 or < −1 (approximately 2-fold and −2-fold, respectively). Common genes expressed differentially in pSBT versus Nl, lMet vs. Nl, and lMet versus pSBT analyses were identified, and genes with either significant serially increased expression from normal tissue to liver mets (lMet > pSBT > Nl) or serially decreased expression (Nl > pSBT > lMet) were selected. The data from the HTA microarrays were analyzed in a similar fashion, and we complied a list of genes satisfying the criteria of significant differential expression of greater than 2-fold increase or decrease in serial expression (from Nls to pSBTs then lMets). The lists obtained from RNA-Seq and HTA expression studies were analyzed, and genes common to both lists were identified.
PCR validation
Genes were selected for qPCR (quantitative polymerase chain reaction) validation based on a combination of the magnitude of the differences in expression observed and involvement in cancer formation or progression as identified by Ingenuity Pathway Analysis (IPA; Ingenuity System Inc., Qiagen). Total RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA), then used as a template for qPCR reactions with Taqman primers from 10 genes meeting the criteria outlined above, as well as the control genes POL2RA and HPRT1 using a 7900HT Fast Real-Time PCR System (Applied Biosystems). These validation assays were carried out using RNA from all 3 tissue sites in 40 additional patients. Assays were performed in quadruplicate, dCt calculated for each gene, and ddCt calculated for each tissue comparison. The concordance of qPCR results with HTA and RNA-Seq results was assessed by confirming statistically significant differential expression between tissue sites (pSBT versus Nl, lMet versus Nl, and lMet versus pSBT) using paired t tests. Gene expression levels were also assessed for the ability to discriminate between pSBTs and lMets using classification trees.
Results
RNA-Seq analysis revealed 1,270 genes in the pSBT versus Nl list that met criteria for presumed clinically relevant upregulation (P < .05 and regularized log-fold change >1), with 1,136/1,270 of these genes also meeting criteria in the lMet versus Nl analysis (Table I) . There were 727 genes in the pSBT versus Nl groups that met criteria for clinically relevant downregulation (P < 0.05 and regularized logfold change < −1), and 598/727 also were downregulated in the lMet versus Nl results. When the same selection criteria of log-fold changes were applied to the lMet versus pSBT list, there were 157 upregulated genes and 565 downregulated genes. A total of 34 of the 157 genes were serially upregulated and also were seen in the 1,136 genes common to the upregulation of pSBT versus Nl and lMet versus Nl (and thus were not highly expressed specifically in the liver or small bowel). Serial downregulation (expression 2-fold lower in lMet than pSBT, and 2-fold lower in pSBT than Nl) was seen in 143 of the 565 genes differentially expressed between pSBT and lMet, from the 598 common downregulated genes identified in the SBT and lMet versus Nl comparisons. Thus, the final numbers for further consideration were 34 serially upregulated genes (expression 2-fold greater in lMet than pSBT, and 2-fold greater in pSBT than Nl) and 143 serially downregulated genes.
HTA analysis identified more differentially expressed genes (P < .05 and fold change <−2 or >2) for both the pSBT and lMet versus Nl comparisons than seen with RNA-Seq. In the pSBT versus Nl analysis, 1,837 upregulated genes and 1,354 downregulated genes were identified (Table I) . Inspection of the lMet versus Nl list established that 401/3,540 upregulated genes discovered also met criteria in the pSBT versus Nl analysis, and 871/3,248 downregulated genes also were present in both lists. The lMet versus pSBT results were 333 upregulated and 482 downregulated genes. A search for common genes to all 3 comparisons identified 34 serially upregulated and 119 serially downregulated genes. The RNA-Seq list (34 upregulated, 143 downregulated) was compared with the list generated from the HTA analysis; the result was 9 common genes that were serially overexpressed and 31 that were serially underexpressed (Supplemental Fig 1) .
From this group, 10 genes were selected for validation, 5 of which were overexpressed and 5 were underexpressed (Table II) . Genes were selected based on a combination of the level of gene expression, direction of expression, availability of quality primers, and published reports of their involvement in cancer pathways. Of these 10 genes, 7 were confirmed to maintain their serial differential expression between all 3 tissue types when validated in 40 additional SBNET patients. Two of these genes (ERRFI1, SERPINA10) had serially increasing expression, while five (DMD, MUC3A, PMP22, SLIT2, TGFBR2) had serially decreasing expression. The serial changes in expression between tissue sites are depicted in box plots with increased expression corresponding with increased -dCt (Fig 1) , while the individual patient levels of gene expression are demonstrated by spaghetti plots (Fig 2) . There was one patient who was an outlier for multiple genes despite unremarkable tumor and clinical characteristics, and this individual is indicated by a dotted line in the spaghetti plots.
ERRFI1 and SERPINA10 were both confirmed to have serial overexpression by qPCR in the validation cohort. While these genes were more highly expressed in lMets versus pSBTs, their expression was less than a 2-fold overexpression (1.91 and 1.75, respectively). In the 3 genes where significant serial expression was not confirmed in the validation group (CAMK1D, GABRQ, SYT13), there were significant differences for pSBTs and lMets versus Nls, but expression levels in lMets and pSBTs were similar (Table III) .
All 5 genes with serial underexpression, as identified by RNASeq and HTA analysis, remained significantly under expressed on qPCR validation. MUC3A had some of the greatest fold changes, with the difference in expression between lMets and Nls being −415.73, and a 31-fold between pSBTs and lMets. PMP22 was the gene that was most consistently underexpressed in lMets, where 36/37 tumors had qPCR expression levels less that 0.7 -dCt, with only one pSBT belonging in this group, to a patient who was a significant outlier for several genes (dotted line in Fig 2) . Gene expression levels of PMP22 predicted accurately 38/40 pSBTs and 35/40 lMets for an overall accuracy rate of 91%. The addition of a SYT13 expression threshold of 3.2 − dCt resulted in correct characterization of 69/72 (96%) primary tumors and metastases, with 8 others being inconclusive, demonstrating the robustness of these serial gene expression studies (Fig 3) .
Of all the disease and function categories, there were 3 somewhat redundant categories identified by IPA that encompassed all 10 genes; these categories were digestive system cancer, abdominal cancer, and epithelial cancer (Table IV) . The top IPA disease groups were cancer, organismal injury, and abnormalities, as well as reproductive system disease. Notable disease and function subcategories where analysis indicated possible upregulation were mammary tumor invasion, vascularization, and cell movement. A network was constructed using 8 of the genes (Fig 4) . Some of the more recognizable central nodes in this network were AKT (which interacts directly with ERRFI1, SLIT2,and TGFBR2), MYC, and MAPK3.
Discussion
The identification of genes that are serially up or downregulated in the progression from normal tissues to primary neoplasmss to metastases has the potential for helping us to understand the molecular pathways important for SBNET tumor progression. One of the challenges of transcriptome data is the large number of genes that are differentially expressed between tissues and how to best sort out candidate genes in an unbiased manner. We utilized the 2 separate transcriptome analysis platforms HTA and RNA-Seq to identify genes with serially increasing (lMet>pSBT>Nl) or serially decreasing expression (Nl>pSBT>lMet). The requirement that candidate genes for validation needed to be serially up-or downregulated using both platforms decreased the number of upregulated gene candidates from 34 (in each HTA and RNA-Seq) to 9 (seen with both), and the number of downregulated genes from 153 for HTA and 177 for RNA-Seq to 40. This approach resulted in a decrease of 74 − 77% in the number of candidate genes, thereby facilitating the selection of genes more likely to have biologic importance rather than spurious changes in expression. From this group of 49 genes, we selected 5 that were serially upregulated and 5 that were downregulated, based on either the greatest differences in expression or those of biologic interest for further validation by qPCR.
Seven of these 10 genes remained significantly differentially expressed in serial fashion by qPCR in an additional 40 SBNET patients. The 3 genes that did not hold up on validation failed due to the lack of a significant increase in lMets compared with pSBTs (Table III) . These 3 genes, however, were still significantly increased in both pSBTs and lMets relative to Nls, suugesting that these 3 genes may still play important roles in aggressiveness of SBNET tumors and could be potential targets for therapy. The 2 genes that did meet our requirements for validation showed significant expression differences of just less than a 2-fold increase between pSBTs and lMets. This observation is in contrast to the downregulated genes which were all confirmed on qPCR validation.
At first glance, the importance of each of these genes is not obvious, because they have not been described as being important in previous exome sequencing, comparative genomic hybridization, or other gene expression studies. Some genes, however, were able to discriminate between pSBTs and lMets based soley on expression levels, while others were noted to interact with familiar pathways such as AKT, and several have been described to be involved in the progression or formation of other cancers.
While the ability to discriminate between pSBT and lMet using gene expression levels does not have particular clinical value, it does help to confirm biologic differences that may be important. The expression of PMP22 below 0.7 -dCt was seen in 35/40 lMets and only 1 pSBT (which was in the one patient who had a significant outlier) indicates that loss of this gene is a common characteristic of lMets. Furthermore, these expression differences indicate that loss/ downregulation of PMP22 is important in SBNET progression or a downstream consequence of other critical changes. Why loss of expression of an integral membrane protein that is important in myelin sheaths would be involved in tumor progression of PMP22 is unclear but could relate to the observation that overexpression results in apoptosis in HEK-293 cells.
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To attempt to identify interactions of serially differentially expressed genes, a gene network was constructed using IPA (Fig 4) . Three of the genes chosen for validation (ERRFI1, SLIT2, and TGFBR2) were noted to have interaction with AKT, which is of particular interest given the current use of Everolimus for treatment of metastatic NETs. The biologic effects of ERRFl1 overexpression are not entirely clear, because ERRFI1 may negatively regulate receptor signaling of epidermal growth factor and the upregulation of ERRFI1 has been described to inhibit cell growth and promote apoptosis.
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SLIT2 overexpression has been associated with increased vascularization of tumors in mice, cell movement of microvascular endothelial cells, and decreased mammary cell invasion. [13] [14] [15] TGFBR2 has an intermediary role in TGF-β induced AKT signaling 16 and seems to play an important role in cancer. Mutation of this gene has been well described in colon cancer, where TGFBR2 provides a selective growth advantage, 17 and its downregulation has been described in neoplastic EC cells. 18 The downregulation of this plasma membrane protein may be secondary to MYC expression, which also increases migration of breast and colorectal cancer cells, [19] [20] [21] and may provide SBNETs a mechanism of avoiding the cytostatic effects of TGFBI. 18, 22 TGFBR2 is located on the plasma membrane, which is ideal for therapeutic targets but may be less valuable, because TGFBR2 is downregulated in the progression to metastasis.
SYT13 is a plasma membrane bound protein involved in the trafficking of neurotransmitters and though it was not overexpressed in lMets versus pSBTs, it was significantly overexpressed in both tumor sites when compared to normal. The expression levels in our tumors, >300 fragments per kilobase of transcript per million mapped reads for pSBT and > 600 for lMet, were almost 10x greater than the greatest average expression levels reported in normal tissues, which are found in the cerebral cortex, pituitary, and cerebellum; are all the sites afeprotected by the blood-brain barrier which makes the SYT13 gene product potentially an excellent target for therapeutics and imaging. Cisplatin decreases phosphorylation of SYT13 23 and may warrant further investigation in SBNETs. Another highly overexpressed gene found in this study was SERPINA10, a serine protease that inhibits factor Xa and X1a. Although not located on the plasma membrane, SERPINA10 has been described previously as being upregulated in both SBNETs and Effect of the expression seen in our study on the listed disease or function as predicted by IPA: Bold, increased activity/formation; Normal, Affected but direction unknown; Underline, decreased activity/formation.
Fig 4.
Gene network constructed from candidate genes using IPA. Red boxes, increased expression in our data set; blue boxes, decreased expression in our data set.
PNETs 24, 25 and thus could play a role in therapy or diagnosis for both types of these NETs.
An important technical issue for studies of differential gene expression is the selection of controls. In the qPCR and HTA experiments, housekeeping genes can be selected to calculate relative levels of gene expression, but this approach is not a reliable method for RNA-Seq. In our study, we had the benefit of having matched normal small bowel tissue from each patient, facilitating comparisons of all genes in the transcriptome. One problem with this strategy is that normal small bowel is a mixture of cell types, and the cells of origin of SBNETs, the EC cells, represent <1% of all cells present. Although these cells could be microdissected by lasercapture and RNA-Seq performed on a more pure precursor cell population, our attempts at these methods has not yielded suitable RNA concentration or quality for genome wide expression studies, and no EC cell lines are available to use as controls. There were advantages to using matched normal samples from individual patients, however. First, this approach gave a frame of reference for comparing pSBTs to lMets, and second, it helped to separate out genes that were highly expressed specifically either in the small bowel or in the liver, rather than being associated with the progression to metastases. For example, transferrin and thrombin were found to be highly expressed in lMets but not Nls or pSBTs. These genes are highly expressed in normal liver tissue, and despite the fact that our liver metastases are generally homogeneous populations of tumor cells without many contaminating hepatocytes, the fact that these liver genes are highly expressed in these NET metastases suggests that just being present in the liver microenvironment leads to this increased expression. The pSBT versus normal comparisons helped similarly to exclude120/342 (35%) genes identified by The Human Protein Atlas (www.proteinatlas.org) as being highly expressed in the small bowel, such as mucin 17 and fatty acid binding protein 2, and which were found at high levels in both pSBTs and Nl tissues in our analysis. These liver and small bowel genes may have otherwise added further noise to a straight comparison of pSBT versus lMet, and thus, using the normal small bowel as a control allowed for further exclusion of genes unlikely to be involved in tumor progression from the final list of candidates.
This comparison of matched tissue samples from 12 patients for gene discovery and an additional 40 patients for gene validation has allowed us to identify a number of genes important in the progression to metastasis. The genes were vetted carefully by requiring serial increasing or decreasing expression from Nl to pSBT to lMet and by demanding that these gene candidates be found by 2 completely different platforms of gene expression using the same RNA samples. As might be expected, not all samples were confirmed to be differentially expressed in serial fashion on validation, but in each of these cases, these genes remained highly differentially expressed in pSBTs and lMets relative to Nl. These results lend further support to the importance of SERPINA10 overexpression and TGFBR2 underexpression in NETs. 18, 24, 25 We also report the novel findings of expression changes in PMP22, SLIT2, and SYT13, with decreased PMP22 expression being a reliable characteristic of lMets, and SYT13 representing a promising imaging and therapeutic target. Our study also sheds light on the importance of the tumor microenvironment on gene expression in tumors, which was suggested through using matched Nl, pSBT, and lMet tissues from each patient. While the results of these expression analyses are of considerable interest, validation of additional genes also will be important. For each of these genes, further evaluation will be important to confirm their role in the sequence of SBNET progression, and their potential utility as diagnostic, imaging, or therapeutic targets.
Discussion
Dr Mary Beth Hughes (Norfolk, VA): It is a very nice paper, and we are fortunate in this disease process that we usually have the primary and the lymph node metastasis and the liver metastasis. Did you look at any of this differential expression in the lymph node metastases?
Dr Kendall J. Keck: As a part of this study and our initial studies, we did not look at the lymph node metastases, but that is on our docket for future studies.
Dr Thomas Fahey, III (New York, NY): Very nice study and great work from you and from Dr Howe's group in really leading the way in this field. I am very interested to know, and especially since you mentioned at the beginning of your talk, if neuroendocrine cells comprise <1 percent of the normal small bowel, why include that in the analysis? Why not just go from tumor to metastasis? Dr Kendall J. Keck: One of the things we noticed with this RNASeq and HTA profiling is that there is some site specific gene expression that is, for the most part, up regulated. So, for example, if we were to compare primary tumors and liver metastasis for the differential expression, we see high expression levels of Transferrin and Thrombin and other liver associated genes.
By using the normal comparison first, we get a set of genes that are up and down regulated for primary, and up and down regulated for liver metastasis. By looking at the common genes, we eliminate those genes that are only specific for the tissue site which limits us to genes that should be involved with neuroendocrine tumors and not other properties.
In addition, there are technical aspects to using EC cells as a control, the first being the limited population; the second being laser captured microdissection being one of the few methods you could use to isolate those cells. Additionally, to do RNA-Seq on this population of cells, you would be looking at single cell or Pico RNA-Seq which rely heavily on multiple rounds of amplification, which may further skew your results in the end.
Dr Thomas Fahey, III (New York, NY): But have you done the analysis where you look just at primary versus metastasis, and does that set of genes differ, and do you come up with a different set of genes?
Dr Kendall J. Keck: You get a different set of genes overall, but as I alluded to, a lot of those genes I would call liver genes, Thrombin, Transferrin, Serum amyloid A1, so you get a lot of noise with that comparison alone. But within that differential comparison are all of the genes that we see in this set currently. By using the described methods, we are able to further select down our gene candidates to hopefully identify the most important genes.
Dr Michael Demeure (Scottsdale, AZ): It is really elegant, and I think a really good effort towards elucidating biology of metastases. I wondered if you controlled at all for differentiation?
Sometimes we know that metastatic cells, if you biopsy them, may be more dedifferentiated tumors or higher grade.
So, did you compare 1 against the other 9, if you will, then the next one against the other nine as far as trying to pull out the driver genes rather than just the nonspecific differentiated genes? Dr Kendall J. Keck: One of our thoughts of continuing from here is with the newer lymph node data to be able to look across and compare the metastatic potential. One of the thoughts we have also had, as you alluded to, is comparing primaries of those with or without metastasis. One of the issues we have at our institution and at several other institutions, is one, there are a large number of our patients that present already having metastasis. And 2, it is difficult to ascertain at the time of surgery which of those people that we do not immediately recognize on imaging as having metastases will subsequently be found to have metastasis. So, the patient selection process for that analysis is difficult.
